Literature DB >> 34097884

P2X7 receptor in multifaceted cellular signalling and its relevance as a potential therapeutic target in different diseases.

Abtar Mishra1, Assirbad Behura1, Ashish Kumar1, Lincoln Naik1, Ashapoorna Swain1, Mousumi Das1, Suman Sudha Sarangi1, Puja Dokania1, Vijaya R Dirisala2, Sujit K Bhutia3, Amit Mishra4, Ramandeep Singh5, Rohan Dhiman6.   

Abstract

P2X7 receptor, a purinergic receptor family member, is abundantly expressed on many cells, including immune, muscle, bone, neuron, and glia. It acts as an ATP-activated cation channel that permits the influx of Ca2+, Na+ and efflux of K+ ions. The P2X7 receptor plays crucial roles in many physiological processes including cytokine and chemokine secretion, NLRP3 inflammasome activation, cellular growth and differentiation, locomotion, wound healing, transcription factors activation, cell death and T-lymphocyte survival. Past studies have demonstrated the up-regulation and direct association of this receptor in many pathophysiological conditions such as cancer, diabetics, arthritis, tuberculosis (TB) and inflammatory diseases. Hence, targeting this receptor is considered a worthwhile approach to lessen the afflictions associated with the disorders mentioned above by understanding the receptor architecture and downstream signalling processes. Here, in the present review, we have dissected the structural and functional aspects of the P2X7 receptor, emphasizing its role in various diseased conditions. This information will provide in-depth knowledge about the receptor and help to develop apt curative methodologies for the betterment of humanity in the coming years.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calcium; Cation channel; NLRP3 inflammasome; P2X7 receptor; Purino-receptor

Mesh:

Substances:

Year:  2021        PMID: 34097884     DOI: 10.1016/j.ejphar.2021.174235

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Effects of a P2X7 receptor antagonist on myenteric neurons in the distal colon of an experimental rat model of ulcerative colitis.

Authors:  Mariá Munhoz Evangelinellis; Roberta Figueiroa Souza; Cristina Eusébio Mendes; Patricia Castelucci
Journal:  Histochem Cell Biol       Date:  2021-10-09       Impact factor: 4.304

2.  Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential Alternative.

Authors:  Kristine Griffett
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-19

3.  P2X7R/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine.

Authors:  Yajuan Wang; Zhengming Shan; Lily Zhang; Shanghua Fan; Yanjie Zhou; Luyu Hu; Yue Wang; Weidong Li; Zheman Xiao
Journal:  J Headache Pain       Date:  2022-07-02       Impact factor: 8.588

4.  Pannexin-1 channel opening is critical for COVID-19 pathogenesis.

Authors:  Ross Luu; Silvana Valdebenito; Eliana Scemes; Antonio Cibelli; David C Spray; Maximiliano Rovegno; Juan Tichauer; Andrea Cottignies-Calamarte; Arielle Rosenberg; Calude Capron; Sandrine Belouzard; Jean Dubuisson; Djillali Annane; Geoffroy Lorin de la Grandmaison; Elisabeth Cramer-Bordé; Morgane Bomsel; Eliseo Eugenin
Journal:  iScience       Date:  2021-11-19

5.  Src family kinases activity is required for transmitting purinergic P2X7 receptor signaling in cortical spreading depression and neuroinflammation.

Authors:  Lingdi Nie; Dongqing Ma; John P Quinn; Minyan Wang
Journal:  J Headache Pain       Date:  2021-12-04       Impact factor: 7.277

Review 6.  Colorectal Cancer and Purinergic Signalling: An Overview.

Authors:  Gabriela Gonçalves Roliano; Juliana Hofstätter Azambuja; Veronica Toniazzo Brunetto; Hannah Elizabeth Butterfield; Antonio Nochi Kalil; Elizandra Braganhol
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

Review 7.  NLRP3 Inflammasome in Diabetic Cardiomyopathy and Exercise Intervention.

Authors:  Yi Sun; Shuzhe Ding
Journal:  Int J Mol Sci       Date:  2021-12-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.